The effectiveness of these therapies in reducing AQP4-ab mediated astrocyte destruction, either through inhibiting plasma cell proliferation or directly altering the effects of AQP4-abs demonstrates the prominent role of B cells in NMO pathogenesis. This evidence concerns the gene AQP4 and neuromyelitis optica.